Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Tandem Diabetes Care, Inc.
Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Tandem Diabetes Care, Inc. (NASDAQ: TNDM) securities between August 3, 2022 and November 2, 2022.
- Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Tandem Diabetes Care, Inc. (NASDAQ: TNDM) securities between August 3, 2022 and November 2, 2022.
- Tandem is a global medical technology company that develops, manufactures, and markets a variety of consumer technologies and software for at-home diabetes care.
- For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
- What Now: Similarly situated shareholders may be eligible to participate in the class action against Tandem Diabetes Care, Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 7, 2023.